Biotech Financing Sentiment At BIO CEO & Investor: Cautiously Bullish
Executive Summary
IPO market is expected to pick up in 2019 after a slow start, due in part to the government shutdown, and VC investment appears steady, but M&A outlook remains mixed.
You may also be interested in...
Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.
Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising
Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.
Bristol/Celgene Made Perfect Sense, But Doesn’t Promise Big M&A Year, EY Says
The conditions that produced a sluggish biopharma M&A environment in 2018 persist, with bolt-on deals like Lilly/Loxo more likely than another mega-merger.